Comparison of Insulin Lispro Protamine Suspension with NPH Insulin in Pregnant Women with Type 2 and Gestational Diabetes Mellitus: Maternal and Perinatal Outcomes

Table 3

Glycaemic control and weight gain in pregnant women receiving ILPS or NPH insulin.

	ILPSg	No. pt	NPHg	No. pt	𝑃
FCBG mg/dL (mmol/L)
Before enrollment
Total	100.7 ± 15.1; (5.6 ± 0.8)	21	100.6 ± 17.4; (5.6 ± 1.0)	25	ns
T2DM	110.0 ± 7.8; (6.1 ± 0.4)	4	109.8 ± 15.8; (6.1 ± 0.9)	12	ns
GDM	98.6 ± 15.8; (5.5 ± 0.9)	17	92.2 ± 14.5; (5.1 ± 0.8)	13	ns
At the end of pregnancy
Total	93.6 ± 13.4**; (5.2 ± 0.7)	30	95.7 ± 10.8*; (5.3 ± 0.6)	28	ns
T2DM	89.2 ± 12.7*; (4.9 ± 0.7)	4	95.5 ± 8.2°; (5.3 ± 0.4)	13	ns
GDM	94.3 ± 13.5*; (5.2 ± 0.7)	26	95.8 ± 12.8*; (5.3 ± 0.7)	15	ns
HbA1c% (mmol/L)
At the end of pregnancy
Total	5.4 ± 1.1; (36.0 ± 12.2)	34	5.3 ± 0.7; (34.4 ± 8.1)	33	ns
T2DM	5.8 ± 1.1; (39.6 ± 12.6)	7	5.4 ± 0.7; (36.8 ± 8.2)	18	ns
GDM	5.3 ± 1.1; (35.0 ± 12.1)	27	5.0 ± 0.6; (31.5 ± 7.2)	15	ns
Weight gain (kg)
At the end of pregnancy
Total	10.4 ± 6.1	53	9.9 ± 4.2	36	ns
T2DM	12.0 ± 6.1	7	10.8 ± 4.9	18	ns
GDM	10.2 ± 6.1	46	9.1 ± 3.3	18	ns

FCBG: fasting capillary blood glucose; T2DM: type 2 diabetes mellitus; GDM: gestational diabetes mellitus.
Paired 𝑡-test’s 𝑃 between preenrollment versus the end of pregnancy: *ns; **0.02; °0.004.